Cytek Biosciences Inc

CTKB is entrenched in a Stage 4 decline with a dominant downtrend across horizons, trading below key moving averages and pressured by a primary Support Failure pattern reinforcing bearish bias. Short-term momentum remains sideways with no oversold signals, and EMAs are acting as resistance. Execution favors selling into any rallies now.

• ↑Q2 2026 revenue $48.1M (+6% YoY), beating expectations
• ↑Recurring revenue 35% of sales; service rev $15.6M (+10% YoY)
• ↓Net loss widened to $12.2M vs $5.6M a year ago